COMPPARE Newsletter: Fall 2020



A Message from Dr. Nancy Mendenhall

Despite the challenges that we and other cancer research studies continue to face in this unprecedented time of COVID-19, COMPPARE has made significant progress toward our ultimate goal of helping prostate cancer patients make informed treatment decisions. Read Dr. Mendenhall’s message.


On the road with COMPPARECOMPPARE Enrolls 750th Patient in August

The COMPPARE team was pleased to announce in August that the study had enrolled 750 patients, 25% of its 3,000-patient goal – learn more about our enrollment progress here.



James M. Slater, MD Proton Treatment & Research Center at Loma Linda University Cancer CenterPartner Site Spotlight: The James M. Slater, MD Proton Treatment & Research Center

Jerry D. Slater, MD, Medical Director of the James M. Slater, MD Proton Treatment & Research Center, discusses how the center increased COMPPARE patient enrollment, retention, and team engagement – follow the conversation here.


Putting Prostate Cancer Awareness into ActionPutting Prostate Cancer Awareness into Motion

September is Prostate Cancer Awareness Month, but how well do awareness and promotion work when it comes to the target audience? As it turns out, actions may speak louder than words – learn more.


COMPPARE on YouTubeLights, Camera, Action: An Interview with Calvin Minor

As co-star of COMPPARE’s recruitment video with his son Tarik, Calvin is a committed patient advocate who believes in the work of the COMPPARE team. “I learned during an office visit that my PSA had escalated. I realized, just when you think you don’t have cancer, you do.” Read Calvin’s story.

Our Health, Our Voice November 4Our Health, Our Voice Information Session Nov. 4

Dr. Nancy Mendenhall, COMPPARE Principal Investigator, will participate in “Our Health, Our Voice: Improving Prostate Cancer Outcomes through Participation in Research” on Wednesday, November 4, 2020, presented by 100 Black Men of America, Inc.


BoBYour Community: A Focus on PSA Screening with BOB

Evidence indicates that more widespread PSA screening would reduce mortality rates and help patients avoid metastatic disease, and the September BOB Tales newsletter wants to get the word out.


Enrollment 10-16-20COMPPARE Study Progress

Want the latest information on COMPPARE? Find out how many patients have enrolled and how many sites are currently enrolling patients on the COMPPARE Study Progress page.


Research reported in this newsletter was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-2017C1-0422). The views, statements, and opinions presented in this newsletter are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or Methodology Committee.


We look forward to sharing our patient-centric news with you. Below you can find an archive of our issues and subscribe to receive COMPPARE Connection in your inbox.


COMPPARE Newsletter Subscription